Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. University Hospital (Vienna), Vienna, Austria

Survival: 24.9 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Adrucil
Country: Austria
City/State/Province: Vienna
Hospital: University Hospital (Vienna)
Journal: Link
Date: 3/2005

Patients: This Phase III study involved 259 women with metastatic breast cancer. The patients were randomly placed into two groups: Group B had 135 patients (median age age 54). Metastatic sites included liver, lung, bone, and lymph node. None of the patients had received anthracyclines prior to treatment.

Treatment: For Group B, the treatment involved three chemotherapeutic agents: fluorouracil, epirubicin, and cyclophosphamide.

Toxicity: In Group B, grade 3-4 toxicities included: neutropenia, thrombocytopenia, anemia, nausea/vomiting, hepatic toxicity and cardiovascular toxicity.

Results: The median overall survival was 24.9 months for Group B (FEC).

Support: Eli Lilly and Company, Bristol-Myers Squibb, and Pharmacia Upjohn provided financial support for this trial. Eli Lilly manufactures and markets gemcitabine. Bristol-Myers Squibb manufactures and markets cyclophosphamide and paclitaxel. Pharmacia Upjohn manufactures and markets epirubicin. Pharmacia Upjohn distributes fluorouracil.

Correspondence: Christoph C. Zielinski, MD

E-mail to a Friend Email Physician More Information